Litigation Details for ChromaDex, Inc. v. Elysium Health, Inc. (D. Del. 2018)

ChromaDex, Inc. v. Elysium Health, Inc. (D. Del. 2018)

Docket		Date Filed	2018-09-17
Court	District Court, D. Delaware	Date Terminated	2021-10-06
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	Plaintiff	Referred To	Jennifer L. Hall
Patents	6,080,428
Link to Docket	External link to docket

Details for ChromaDex, Inc. v. Elysium Health, Inc. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-09-17				External link to document
2018-09-17	231	Redacted Document	..... 74 2. Bova (U.S. Patent No . 6,080,428) .......................................…Asserted Patents Patents for "isolated" polypeptides. Patent, 9:23…both patents, given that the relevant understanding Patent and the '807 Patent and NR… that the patents are directed to patentable patentable subject matter… United States Patent (10) Patent No.:	External link to document

ChromaDex, Inc. v. Elysium Health, Inc. Litigation Summary and Patent Analysis, 1:18-cv-01434

Last updated: August 7, 2026

ChromaDex sued Elysium Health in the U.S. District Court for the District of Delaware in 2018, alleging that Elysium’s Basis product infringed ChromaDex patents covering nicotinamide riboside, or NR. The dispute centered on two issued patents, U.S. Patent Nos. 8,197,807 and 8,383,086. The case ended through a confidential settlement and dismissal rather than a public trial verdict establishing infringement or patent validity.

What was ChromaDex v. Elysium Health about?

ChromaDex alleged that Elysium’s Basis dietary supplement used NR in a manner covered by ChromaDex’s patent portfolio. Basis contains nicotinamide riboside chloride and pterostilbene and is marketed for supporting NAD+ levels.

ChromaDex’s commercial position rested on its rights relating to Tru Niagen, its NR product, and its licensing and supply relationships for NR. ChromaDex asserted that Elysium entered the NR supplement market using technology covered by ChromaDex’s patents without authorization.

The case was filed as:

Field	Detail
Case	ChromaDex, Inc. v. Elysium Health, Inc.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:18-cv-01434
Filing year	2018
Plaintiff	ChromaDex, Inc.
Defendant	Elysium Health, Inc.
Product at issue	Elysium Basis
Principal technology	Nicotinamide riboside compositions and uses
Outcome	Settlement and dismissal
Public merits verdict	None

The case was a commercial patent dispute between competing NR suppliers and supplement brands. It was not an FDA generic-drug case and did not involve an abbreviated new drug application, a Paragraph IV certification, or an Orange Book listing.

What patents did ChromaDex assert against Elysium?

ChromaDex’s complaint identified U.S. Patent Nos. 8,197,807 and 8,383,086. Both patents relate to compositions and methods involving nicotinamide riboside.

Patent	General subject matter	Relevance to dispute
U.S. 8,197,807	Nicotinamide riboside compositions and methods of use	Asserted against Basis-related activity
U.S. 8,383,086	Nicotinamide riboside compositions and methods of use	Asserted against Basis-related activity

The patents arose from an early NR research and development program associated with Dartmouth College and subsequently licensed to ChromaDex. The asserted technology generally concerns the use of NR to increase NAD+ concentrations and support related biological functions.

The complaint alleged infringement based on Elysium’s manufacture, marketing, sale, and distribution of Basis. ChromaDex sought damages, injunctive relief, and other remedies available under the Patent Act. [1]

What did the asserted patents cover?

The asserted claims were directed to combinations of:

• Nicotinamide riboside;
• Pharmaceutical or nutritional compositions containing NR;
• Administration of NR to increase NAD+ or related metabolites; and
• Uses associated with cellular energy, aging, metabolic function, or NAD+ biology.

The scope of protection depended on the specific claim language. The existence of NR in a supplement did not, by itself, establish infringement. ChromaDex had to show that Basis met every limitation of at least one asserted claim, either literally or under the doctrine of equivalents.

The dispute therefore involved claim construction and product-specific infringement analysis. The litigation record did not produce a public final judgment determining that Basis infringed either patent.

When were the ChromaDex NR patents expected to expire?

The asserted patents originated from applications filed in the late 2000s and were subject to the 20-year patent-term framework applicable to their filing dates, subject to patent-term adjustment and any terminal-disclaimer issues.

Patent	Approximate statutory term basis	Expected term range
U.S. 8,197,807	Priority chain originating in 2007	Approximately late 2027, subject to adjustment
U.S. 8,383,086	Related continuation or successor application	Approximately late 2027, subject to adjustment

The exact enforceable expiration date must be taken from the USPTO patent record because patent-term adjustment can change the nominal expiration date. The settlement ended the case before the court issued a public ruling defining the practical surviving scope of the asserted claims.

The patent term was commercially important because NR products were sold primarily as dietary supplements, where a patent-based injunction could have affected formulation, supply, branding, and distribution even without FDA drug approval.

Did Elysium file a Paragraph IV challenge?

No. The case was not a Paragraph IV Hatch-Waxman dispute.

Elysium’s Basis product was marketed as a dietary supplement rather than an FDA-approved prescription drug. It therefore did not involve:

• An ANDA;
• An FDA Orange Book listing;
• A Paragraph IV certification;
• A 30-month regulatory stay;
• FDA small-molecule exclusivity; or
• A conventional generic-launch date.

The relevant market-entry risk was ordinary patent litigation, not the abbreviated approval pathway used by generic-drug manufacturers.

What was the litigation timeline?

Date	Event
2018	ChromaDex filed the patent infringement action in the District of Delaware
2018-2019	Elysium answered and asserted defenses and counterclaims
2019-2020	The parties litigated claim construction, discovery, and pretrial issues
2020-2021	The court issued substantive procedural and claim-construction rulings
2021	The parties resolved the dispute through settlement
After settlement	The action was dismissed, ending the federal case without a public trial verdict

The case involved the typical Delaware patent-litigation stages: pleadings, infringement and invalidity contentions, technical discovery, expert analysis, and claim-construction proceedings. Public materials do not establish a final adjudication of infringement, validity, or damages.

What defenses and counterclaims did Elysium raise?

Elysium disputed ChromaDex’s infringement allegations and challenged the enforceability and validity of the asserted patent rights. The defense strategy in this type of case generally turns on:

• Non-infringement;
• Anticipation;
• Obviousness;
• Lack of written description or enablement;
• Claim construction;
• Patent exhaustion or licensing issues, where applicable; and
• Restrictions on the scope of ChromaDex’s commercial rights.

Elysium also pursued counterclaims and defenses concerning ChromaDex’s conduct in the NR market. The dispute had a competitive dimension because ChromaDex was both a patent holder and a supplier or marketer of NR products. The public record does not provide a final merits ruling resolving those competition-related claims.

The absence of a final merits decision limits the precedential value of the case. The litigation did not establish a binding judicial rule that all NR supplements infringe ChromaDex patents, nor did it invalidate the asserted patents across the market.

What was the settlement outcome?

The parties settled the action and the court dismissed the case. The principal commercial terms were not publicly disclosed in the court’s dismissal record.

The settlement means:

1. There was no public jury verdict.
2. There was no publicly reported damages award.
3. There was no permanent injunction issued after trial.
4. The court did not issue a final public ruling holding the asserted claims valid and infringed.
5. The case cannot be used as a final adjudication that Elysium’s Basis product infringed the asserted patents.

A confidential settlement can still include product, licensing, supply, payment, branding, or future-conduct provisions. The public docket does not establish the full scope of any such provisions. The dismissal closed the specific action but did not necessarily eliminate every patent, contract, or competition issue between the companies outside the released claims.

What is the FDA and Orange Book status of the dispute?

The dispute had no Orange Book component.

ChromaDex’s Tru Niagen and Elysium’s Basis are dietary supplement products, not FDA-approved prescription drugs. Their commercial status is governed primarily by the Federal Food, Drug, and Cosmetic Act provisions applicable to dietary supplements, including manufacturing, labeling, and safety requirements.

Regulatory issue	Status
FDA-approved drug	No
Orange Book listing	None
ANDA litigation	None
Paragraph IV challenge	None
Biologic license application	None
Biosimilar pathway	Not applicable
Primary legal risk	Patent, contract, competition, and supplement-regulatory issues

The lack of Orange Book listing does not eliminate patent risk. It means that patent disputes must proceed through conventional district-court litigation or, where available, inter partes review and other patent procedures.

How strong was ChromaDex’s patent estate?

ChromaDex’s patent position had commercial value because the asserted patents were directed to a relatively specific ingredient, nicotinamide riboside, rather than to a broad category such as all NAD+ precursors.

The estate’s strengths included:

• Early filing dates in the NR field;
• Patent claims directed to compositions and uses;
• A close relationship between the claimed technology and commercial NR products;
• Licensing and supply-chain relevance; and
• The ability to assert rights against competing NR products without relying on FDA exclusivity.

The estate also had material weaknesses:

• Claim scope depended on technical limitations and product composition;
• Patent validity could be challenged under anticipation and obviousness standards;
• Dietary supplement products can be reformulated;
• Competitors can pursue non-infringing formulations or alternative NAD+ precursors;
• A settlement provided no public validity ruling; and
• The commercial value of any particular claim would decline as the patents approached expiration.

The litigation therefore demonstrated enforcement capability but did not produce a public ruling that would materially strengthen ChromaDex’s patent estate against the broader NR market.

What generic entry risks existed for Elysium and other NR competitors?

Traditional generic entry risk was not applicable because Basis was not an approved prescription drug. The relevant competitive risks were:

Reformulation risk

A competitor could attempt to design around claims requiring particular NR concentrations, combinations, excipients, dosage forms, or methods of administration.

Ingredient-supply risk

A patent dispute could affect access to NR suppliers, especially where a supplier’s process, specifications, or commercial use was connected to ChromaDex’s licensed technology.

Branding and labeling risk

Even if a competing product avoided patent infringement, product claims concerning NAD+, aging, metabolism, or disease-related benefits could create separate FDA or Federal Trade Commission exposure.

Market substitution

Competitors could use nicotinamide mononucleotide, niacin, niacinamide, or other NAD+ precursors. Such products would raise different patent and regulatory questions.

Litigation-reentry risk

A settlement resolving one case does not necessarily prevent later litigation involving new products, new patents, new sales channels, or conduct outside the settlement release.

Did the case affect ChromaDex’s revenue exposure?

The litigation had potential revenue implications for ChromaDex because NR product sales, ingredient supply, licensing, and brand positioning were commercially linked.

A successful injunction could have restricted Elysium’s sale of Basis or increased Elysium’s cost of goods through licensing or supply arrangements. A defense victory could have weakened ChromaDex’s ability to control NR-related commercial activity.

The public case record does not establish a final damages award or a quantified revenue transfer. ChromaDex’s public filings identify litigation, intellectual-property rights, licensing, and NR commercialization as business risks, but the settlement’s financial terms were not publicly disclosed in the dismissal record. [2]

The principal financial conclusion is therefore directional: the settlement removed the immediate litigation cost and injunction risk from this action, while preserving uncertainty about the value and practical enforceability of the remaining NR portfolio.

Which companies were affected by the dispute?

The direct parties were ChromaDex and Elysium Health. The broader competitive set included companies selling:

• NR-containing supplements;
• NAD+ products;
• Nicotinamide mononucleotide products;
• Vitamin B3 formulations; and
• Anti-aging and longevity products.

The case was commercially relevant to ingredient suppliers, contract manufacturers, supplement brands, retailers, and investors assessing exclusivity in the NAD+ category.

It did not establish that ChromaDex held a blanket monopoly over all NAD+ supplements. The asserted patents addressed defined NR compositions and uses, while competing products could present different technical and legal profiles.

What patent litigation affects ChromaDex and Elysium after settlement?

The 1:18-cv-01434 action itself is closed. Its settlement eliminates the pending claims in that case but does not provide a public judicial determination of the parties’ broader patent positions.

For future diligence, the relevant issues are:

• Whether later-issued ChromaDex continuation patents cover new NR formulations;
• Whether Elysium or other competitors challenge ChromaDex patents through the USPTO;
• Whether new products use different NR salts, dosages, excipients, or delivery systems;
• Whether supply agreements contain patent or field-of-use restrictions;
• Whether the settlement imposes continuing obligations; and
• Whether the parties bring later actions involving patents or conduct outside the settlement release.

Key Takeaways

• ChromaDex sued Elysium in Delaware in 2018 over Elysium’s Basis NR supplement.
• The asserted patents were U.S. Patent Nos. 8,197,807 and 8,383,086.
• The case involved nicotinamide riboside compositions and methods, not an FDA-approved drug.
• There was no Paragraph IV certification, ANDA, Orange Book listing, or biosimilar pathway.
• The parties settled and the case was dismissed without a public infringement, validity, or damages verdict.
• The patents originated from a late-2000s priority chain and had projected terms extending into approximately 2027, subject to patent-term adjustment.
• The settlement reduced immediate litigation exposure but did not establish a market-wide monopoly over NR or all NAD+ products.
• Future risk depends on continuation patents, product reformulation, licensing terms, supply arrangements, and new litigation.

FAQs About ChromaDex v. Elysium Health

Did ChromaDex win its patent lawsuit against Elysium?

No public trial verdict established a ChromaDex victory. The case ended through settlement and dismissal.

Did Elysium stop selling Basis?

The public dismissal record does not establish that Elysium permanently stopped selling Basis. Settlement terms were not publicly disclosed in full.

Are ChromaDex’s NR patents still relevant?

Yes. The patents’ remaining term, continuation applications, licensing rights, and claim scope can affect NR products until expiration or invalidation.

Can a company sell an NR supplement without a ChromaDex license?

Patent exposure depends on the specific product, claims, manufacturing process, and applicable rights. NR products are not automatically covered by every ChromaDex patent.

Is Tru Niagen an FDA-approved drug?

No. Tru Niagen is marketed as a dietary supplement, not as an FDA-approved prescription drug.

References

1. ChromaDex, Inc. v. Elysium Health, Inc., No. 1:18-cv-01434, U.S. District Court for the District of Delaware, docket and pleadings (2018-2021).

2. ChromaDex, Inc. Annual Report, Form 10-K, filings discussing intellectual property, litigation, licensing, and NR commercialization. U.S. Securities and Exchange Commission.

3. U.S. Patent No. 8,197,807, “Nicotinamide riboside compositions and methods of use.” United States Patent and Trademark Office.

4. U.S. Patent No. 8,383,086, “Nicotinamide riboside compositions and methods of use.” United States Patent and Trademark Office.

5. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations.

6. U.S. Food and Drug Administration. (n.d.). Dietary supplement products and ingredients.